Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …

Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through
vascular endothelial growth factor (VEGF) have been shown to play important roles in …

Abstract Lessons Learned. Temsirolimus maintenance therapy after docetaxel induction
chemotherapy is safe in patients with castration-resistant prostate cancer, although …

Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …

BACKGROUND: The phosphatase and tensin homolog (PTEN) tumor suppressor gene is
deregulated in many advanced prostate cancers, leading to activation of the …

Background Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced
castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies …

Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …